Wei et al. reported a successful case of furmonertinib rechallenge in a patient with EGFR-mutant lung adenocarcinoma who had developed osimertinib-induced interstitial lung disease (ILD) (Wei et al., 2025). Here, EGFR is linked to lung adenocarcinoma.